Matthew E Falagas1,2, Tilemachos Skalidis1,3, Konstantinos Z Vardakas1,4, Nicholas J Legakis1,3. 1. Research Center of Infectious Diseases, Iaso Group Hospitals, Athens, Greece. 2. Department of Medicine, Tufts University School of Medicine, Boston, MA, USA. 3. Central Laboratories, Iaso Group Hospitals, Athens, Greece. 4. Department of Medicine-Infectious Diseases, Iaso General Hospital, Iaso Group, Athens, Greece.
Abstract
Background: Cefiderocol (S-649266), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases. Methods: A collection of carbapenem-resistant Gram-negative bacteria isolated from clinical specimens in 18 Greek hospitals was tested for susceptibility to cefiderocol, meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin and tigecycline. Broth microdilution plates were used to determine MICs. Results: In total 189 non-fermentative Gram-negative bacteria (107 Acinetobacter baumannii and 82 Pseudomonas aeruginosa ) and 282 Enterobacteriaceae (including 244 Klebsiella pneumoniae , 14 Enterobacter cloacae and 11 Providencia stuartii ) were studied. For both A. baumannii and P. aeruginosa the MIC 90 of cefiderocol was 0.5 mg/L. For K. pneumoniae , E. cloacae and P. stuartii the MIC 90 of cefiderocol was 1, 1 and 0.5 mg/L, respectively. Tigecycline was the second most active antibiotic, followed by colistin. Conclusions: Cefiderocol exhibited greater antimicrobial activity in vitro against carbapenem-resistant Gram-negative bacteria than comparator antibiotics.
Background: Cefiderocol (S-649266), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases. Methods: A collection of carbapenem-resistant Gram-negative bacteria isolated from clinical specimens in 18 Greek hospitals was tested for susceptibility to cefiderocol, meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin and tigecycline. Broth microdilution plates were used to determine MICs. Results: In total 189 non-fermentative Gram-negative bacteria (107 Acinetobacter baumannii and 82 Pseudomonas aeruginosa ) and 282 Enterobacteriaceae (including 244 Klebsiella pneumoniae , 14 Enterobacter cloacae and 11 Providencia stuartii ) were studied. For both A. baumannii and P. aeruginosa the MIC 90 of cefiderocol was 0.5 mg/L. For K. pneumoniae , E. cloacae and P. stuartii the MIC 90 of cefiderocol was 1, 1 and 0.5 mg/L, respectively. Tigecycline was the second most active antibiotic, followed by colistin. Conclusions: Cefiderocol exhibited greater antimicrobial activity in vitro against carbapenem-resistant Gram-negative bacteria than comparator antibiotics.
Authors: George G Zhanel; Alyssa R Golden; Sheryl Zelenitsky; Karyn Wiebe; Courtney K Lawrence; Heather J Adam; Temilolu Idowu; Ronald Domalaon; Frank Schweizer; Michael A Zhanel; Philippe R S Lagacé-Wiens; Andrew J Walkty; Ayman Noreddin; Joseph P Lynch Iii; James A Karlowsky Journal: Drugs Date: 2019-02 Impact factor: 9.546
Authors: Delaney Burnard; Gemma Robertson; Andrew Henderson; Caitlin Falconer; Michelle J Bauer; Kyra Cottrell; Ian Gassiep; Robert Norton; David L Paterson; Patrick N A Harris Journal: Antimicrob Agents Chemother Date: 2021-01-20 Impact factor: 5.191
Authors: D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern Journal: Anaesthesist Date: 2019-11 Impact factor: 1.041
Authors: Thomas M Harper; Cynthia M June; Magdalena A Taracila; Robert A Bonomo; Rachel A Powers; David A Leonard Journal: Biochem J Date: 2018-01-11 Impact factor: 3.857